ArriVent BioPharma, Inc. Common Stock

NASDAQ:AVBP

Biotechnology

Healthcare
$10.90 +1.40%

+$0.44 today

Market cap
$563.78M
Beta
1.42
P/E (TTM)
-9.8
EPS (TTM)
-$3.22
52W Low $16.10High $33.62

Volume 2.70M

Average 0.50M

Balance Sheet

Inspect the capital base behind the business.

Assets

$333.17M

FY 2025 · Annual

+21.2% YoY

Liabilities

$25.95M

FY 2025 · Annual

+50.1% YoY

Equity

$307.22M

FY 2025 · Annual

+19.2% YoY

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents37.28M163.37M150.39M74.29M45.54M
Short-term Investments000144.57M267.28M
Net Receivables000500K60K
Inventory00000
Other Current Assets5.64M18.92M9.21M7.21M20.02M
Total Current Assets42.95M182.62M159.97M226.98M332.9M
Property, Plant & Equipment (Net)0139K291K154K13K
Goodwill00000
Intangible Assets00000
Long-term Investments00047.68M0
Tax Assets00000
Other Non-current Assets87K72K2.84M126K259K
Total Non-current Assets87K211K3.13M47.96M272K
Total Assets43.04M182.83M163.1M274.94M333.17M
Account Payables293K3.09M4.53M3.78M5.93M
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities0004.16M6.55M
Total Current Liabilities1.82M8.36M11.62M17.27M25.95M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities011K177K14K0
Total Liabilities1.82M8.37M11.8M17.29M25.95M
Common Stock0003K4K
Retained Earnings(51.61M)(88.51M)(157.85M)(238.33M)(404.64M)
Accumulated OCI(2K)00(211K)14K
Other Stockholders Equity(0)0000
Minority Interest00000
Total Equity41.22M174.46M151.3M257.65M307.22M
Total Debt0139K317K176K14K
Net Debt(37.28M)(163.23M)(150.07M)(74.12M)(45.53M)

Balance Sheet

Assets, liabilities & equity

Cash & Equivalents$62.1M
Short-term Investments$264.3M
Other Current$22.3M
Total Current Assets$348.7M
PP&E (Net)$370.0K
Other Non-current$225.0K
Total Non-current Assets$595.0K
Total Assets$349.3M

Analysis

Selected assets total $349.3M for Latest. The largest visible component is Short-term Investments at $264.3M, about 75.7% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportNov 9, 2026
10-QQuarterly reportNov 9, 2026
SC 13G/ASC 13G/A filingNov 5, 2026
4Statement of changes in beneficial ownershipNov 2, 2026
8-KCurrent reportOct 26, 2026

How much cash does AVBP have?

ArriVent BioPharma, Inc. Common Stock (AVBP) reported $45.54M in cash and equivalents in fiscal 2025.

How much debt does AVBP carry?

ArriVent BioPharma, Inc. Common Stock (AVBP) reported $14,000.00 of total debt, with net debt of -$45.53M.